23:49 , Aug 8, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Neurology Mouse studies suggest CHRM3 antagonists could help treat demyelination diseases. In a mouse model of CNS demyelination, transplantation into the corpus callosum of CHRM3-deficient human oligodendrocyte progenitor cells (OPCs) increased the number of mature...
18:58 , May 9, 2018 |  BC Innovations  |  Translation in Brief

Dissecting rare gliomas

In an April Science study, researchers from Massachusetts General Hospital and Harvard Medical School identified a subpopulation of malignant cells driving disease progression in rare pediatric gliomas with mutated histone H3 K27M using single-cell RNA...
19:27 , Jan 4, 2018 |  BC Innovations  |  Translation in Brief

ArunA’s exosome entrance

Stem cell manufacturer ArunA Biomedical Inc. has announced a pivot into the exosome therapeutic space, as well as publication of the first data showing its neural stem cell-derived exosomes and other extracellular vesicles are effective...
23:50 , Dec 6, 2017 |  BC Extra  |  Preclinical News

BCAS1 could identify remyelinating cells

In a paper published in Science Translational Medicine, researchers at the Max Planck Institute for Experimental Medicine and their German colleagues show that breast cancer amplified sequence 1 (BCAS1) can be used a marker of...
18:59 , Nov 3, 2017 |  BC Week In Review  |  Financial News

Asterias raises $10.4M in registered direct offering

On Oct. 19, Asterias Biotherapeutics Inc. (NYSE-M:AST) closed a registered direct offering led by Chardan, raising $10.4 million through the sale of 4 million shares at $2.60. The company said it will use the funds to...
18:04 , Aug 29, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Nerve damage Mouse studies suggest FGF21 could help treat spinal cord damage associated with traumatic brain injury (TBI) and multiple sclerosis. In postmortem tissue samples from MS patients, levels of the FGF21 signaling marker klotho...
21:34 , Aug 3, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: July 2017

New Therapeutic Targets and Biomarkers: July 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during July 2017. Therapeutic targets are defined as any protein, gene or other molecule...
20:43 , Jul 25, 2017 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Fusion proteins Fusion proteins consisting of an engineered IgG1 fragment and antigens could be used to clear disease-associated or imaging antibodies from circulation. The fusion protein consists of two parts: an IgG1 Fc fragment engineered...
20:34 , Jul 25, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Cell culture and mouse studies suggest nanoparticles loaded with siRNAs targeting SOX2, OLIG2, SALL2, and POU3F2 could help treat the proneural subtype of glioblastoma multiforme (GBM). In two proneural GBM cell lines,...
16:59 , May 31, 2017 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Mouse studies suggest promoting ERDR1 expression could help treat MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, overexpression of ERDR1 in T cells decreased the number of MOG-specific T...